drugset / Trial / NCT04862663
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Timeline
- Start
- 2021-05-10
- Primary completion
- 2027-11-01
- Completion
- 2029-08-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 50 mg | — |
| Subject | Abemaciclib | Small molecule | 100 mg | — |
| Subject | Abemaciclib | Small molecule | 150 mg | — |
| Subject | Capivasertib | Small molecule | 320 mg | Oral |
| Subject | Capivasertib | Small molecule | 400 mg | Oral |
| Subject | Fulvestrant | Small molecule | 500 mg | — |
| Subject | Palbociclib | Small molecule | 100 mg | — |
| Subject | Palbociclib | Small molecule | 125 mg | — |
| Subject | Ribociclib | Small molecule | 200 mg | — |
| Subject | Ribociclib | Small molecule | 400 mg | — |
| Subject | Ribociclib | Small molecule | 600 mg | — |